MX2021014572A - Metodo para proporcionar la administracion segura de un anticuerpo anti-cd40. - Google Patents

Metodo para proporcionar la administracion segura de un anticuerpo anti-cd40.

Info

Publication number
MX2021014572A
MX2021014572A MX2021014572A MX2021014572A MX2021014572A MX 2021014572 A MX2021014572 A MX 2021014572A MX 2021014572 A MX2021014572 A MX 2021014572A MX 2021014572 A MX2021014572 A MX 2021014572A MX 2021014572 A MX2021014572 A MX 2021014572A
Authority
MX
Mexico
Prior art keywords
antibody
providing
safe administration
administration
methods
Prior art date
Application number
MX2021014572A
Other languages
English (en)
Spanish (es)
Inventor
Michael Streit
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021014572A publication Critical patent/MX2021014572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021014572A 2019-05-28 2020-05-27 Metodo para proporcionar la administracion segura de un anticuerpo anti-cd40. MX2021014572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853488P 2019-05-28 2019-05-28
PCT/IB2020/055023 WO2020240434A1 (en) 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody

Publications (1)

Publication Number Publication Date
MX2021014572A true MX2021014572A (es) 2022-03-17

Family

ID=70918772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014572A MX2021014572A (es) 2019-05-28 2020-05-27 Metodo para proporcionar la administracion segura de un anticuerpo anti-cd40.

Country Status (13)

Country Link
US (1) US20230174658A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976651A1 (cg-RX-API-DMAC7.html)
JP (2) JP7755999B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220012918A (cg-RX-API-DMAC7.html)
CN (1) CN113939535A (cg-RX-API-DMAC7.html)
AU (1) AU2020284706A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023906A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142226A1 (cg-RX-API-DMAC7.html)
IL (1) IL288288A (cg-RX-API-DMAC7.html)
MA (1) MA56027A (cg-RX-API-DMAC7.html)
MX (1) MX2021014572A (cg-RX-API-DMAC7.html)
SG (1) SG11202112909SA (cg-RX-API-DMAC7.html)
WO (1) WO2020240434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122355A2 (en) * 2021-12-24 2023-06-29 Sapience Therapeutics, Inc. Methods of treating or preventing infusion-related reactions
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
EP3180087B1 (en) * 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
WO2018160917A1 (en) * 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer

Also Published As

Publication number Publication date
SG11202112909SA (en) 2021-12-30
BR112021023906A2 (pt) 2022-01-25
CA3142226A1 (en) 2020-12-03
JP2026004525A (ja) 2026-01-14
JP2022534494A (ja) 2022-08-01
CN113939535A (zh) 2022-01-14
IL288288A (en) 2022-01-01
MA56027A (fr) 2022-04-06
KR20220012918A (ko) 2022-02-04
US20230174658A1 (en) 2023-06-08
JP7755999B2 (ja) 2025-10-17
WO2020240434A1 (en) 2020-12-03
AU2020284706A1 (en) 2021-12-16
EP3976651A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
WO2017152085A8 (en) Combination therapy with anti-cd73 antibodies
PH12021500014A1 (en) Fused ring compounds
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
MX2020007092A (es) Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos.
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
MX388694B (es) Compuestos neuroactivos y metodos de uso de los mismos.
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
MX2017003181A (es) Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
EA202190633A1 (ru) Лекарственные формы для применения в педиатрии, способы получения и применения
EA201891342A1 (ru) Изоиндольные соединения
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds